BR9907084A - "composição em pó, de cor amarela, administrável oralmente, e processo para a preparação da mesma" - Google Patents

"composição em pó, de cor amarela, administrável oralmente, e processo para a preparação da mesma"

Info

Publication number
BR9907084A
BR9907084A BR9907084-7A BR9907084A BR9907084A BR 9907084 A BR9907084 A BR 9907084A BR 9907084 A BR9907084 A BR 9907084A BR 9907084 A BR9907084 A BR 9907084A
Authority
BR
Brazil
Prior art keywords
product
preparing
yellow
orally administrable
powdered composition
Prior art date
Application number
BR9907084-7A
Other languages
English (en)
Other versions
BRPI9907084B8 (pt
BRPI9907084B1 (pt
Inventor
Masahiro Onodera
Kiyoshi Yasui
Yasushi Murai
Katsuharu Iinuma
Tatsuo Watanabe
Masamichi Sukegawa
Toyomi Sato
Original Assignee
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha filed Critical Meiji Seika Kaisha
Publication of BR9907084A publication Critical patent/BR9907084A/pt
Publication of BRPI9907084B1 publication Critical patent/BRPI9907084B1/pt
Publication of BRPI9907084B8 publication Critical patent/BRPI9907084B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Patente de Invenção para <B>"COMPOSIçãO EM Pó, DE COR AMARELA, ADMINISTRáVEL ORALMENTE, E PROCESSO PARA A PREPARAçãO DA MESMA"<D> Processos são providos para a preparação de composições em pó, de cor amarela, administráveis oralmente, consistindo essencialmente de partículas compostas de uma mistura homogênea de uma substância do Cefditoren pivoxil amorfa com um aditivo alto molecular solúvel em água. Estas composições podem ser produzidas por dissolução da substância cristalina de Cefditoren pivoxil e aditivo de alto molecular solúvel em água em uma solução aquosa de um ácido, então neutralizar a solução resultante, para co-precipitar o produto, e secagem do assim precipitado produto, seguido por recuperação do produto na forma das partículas acima mencionadas.
BRPI9907084A 1998-01-07 1999-01-07 processo para a preparação de uma composição compreendendo cefalosporina amorfa cristalograficamente estável BRPI9907084B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP192098 1998-01-07
PCT/JP1999/000020 WO1999034832A1 (fr) 1998-01-07 1999-01-07 Compositions de cephalosporine amorphes, stables du point de vue cristallographique et procede de preparation de ces compositions

Publications (3)

Publication Number Publication Date
BR9907084A true BR9907084A (pt) 2000-10-17
BRPI9907084B1 BRPI9907084B1 (pt) 2017-04-25
BRPI9907084B8 BRPI9907084B8 (pt) 2021-05-25

Family

ID=11515039

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9907084A BRPI9907084B8 (pt) 1998-01-07 1999-01-07 processo para a preparação de uma composição compreendendo cefalosporina amorfa cristalograficamente estável

Country Status (23)

Country Link
US (2) US6342493B1 (pt)
EP (1) EP1051978B1 (pt)
JP (1) JP3413406B2 (pt)
KR (1) KR100435315B1 (pt)
CN (1) CN1151845C (pt)
AU (1) AU736555B2 (pt)
BR (1) BRPI9907084B8 (pt)
CA (1) CA2316841C (pt)
CZ (1) CZ302082B6 (pt)
EA (1) EA002881B1 (pt)
ES (1) ES2393972T3 (pt)
HK (1) HK1035148A1 (pt)
HU (1) HU230295B1 (pt)
ID (1) ID25469A (pt)
IL (2) IL137004A0 (pt)
NZ (1) NZ505871A (pt)
PL (1) PL194097B1 (pt)
PT (1) PT1051978E (pt)
SK (1) SK286631B6 (pt)
TR (1) TR200001903T2 (pt)
TW (1) TW587946B (pt)
UA (1) UA70311C2 (pt)
WO (1) WO1999034832A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL194097B1 (pl) * 1998-01-07 2007-04-30 Meiji Seika Kaisha Kompozycja zawierająca krystalograficznie trwałą amorficzną cefalosporynę i sposób jej wytwarzania
CZ302015B6 (cs) 1999-10-08 2010-09-08 Affinium Pharmaceuticals, Inc. Inhibitory Fab I
ATE420640T1 (de) 2001-04-06 2009-01-15 Affinium Pharm Inc Fab-i-inhibitoren
AU2002253642B2 (en) * 2001-04-26 2007-05-24 Meiji Seika Kaisha, Ltd. Amorphous cefditoren pivoxil composition and process for producing the same
CA2500712C (en) * 2002-10-02 2011-08-09 Meiji Seika Kaisha, Ltd. Antibiotic pharmaceutical composition with improved oral absorbability
DK1575951T3 (da) 2002-12-06 2014-09-15 Debiopharm Int Sa Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
EP1608377B1 (en) * 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
WO2004113451A1 (ja) * 2003-06-20 2004-12-29 Meiji Seika Kaisha, Ltd. 難溶性物質と水溶性高分子との共沈物およびその製造方法
ATE539738T1 (de) 2003-10-08 2012-01-15 Meiji Seika Pharma Co Ltd Nichtkristalline antibakterielle zusammensetzung mit cefditoren-pivoxil
WO2005044824A2 (en) * 2003-11-07 2005-05-19 Ranbaxy Laboratories Limited Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
WO2005082330A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Co-precipitated amorphous cefditoren pivoxil and dosage forms comprising the same
SI1828167T1 (sl) 2004-06-04 2014-12-31 Debiopharm International Sa Forum "Apres-Demain" Akrilamidni derivati kot anitibiotična sredstva
US20080069879A1 (en) * 2006-05-02 2008-03-20 Ravishekhar Bhiwgade Stable solid dosage form containing amorphous cefditoren pivoxil and process for preparation thereof
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
WO2008057058A1 (en) * 2006-11-10 2008-05-15 Nobel Ilac Sanayii Ve Ticaret As Oral pharmaceutical compositions
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
CN101560216B (zh) * 2009-05-27 2011-06-15 上海交通大学 头孢妥仑酯的制备方法
WO2012010938A2 (en) * 2010-07-23 2012-01-26 Lupin Limited Pharmaceutical compositions of cefditoren pivoxil
SI2623498T1 (sl) 2010-09-30 2016-03-31 Toyama Chemical Co., Ltd. Natrijeva sol 6-fluoro-3-hidroksi-2-pirazinkarboksamida
JP5936546B2 (ja) 2010-09-30 2016-06-22 富山化学工業株式会社 ６−フルオロ−３−ヒドロキシ−２−ピラジンカルボキサミドのメグルミン塩
MX356695B (es) 2012-06-19 2018-06-11 Debiopharm Int Sa Profarmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)me til)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il) acrilamida.
EP3039011A1 (en) * 2013-08-29 2016-07-06 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
WO2016114727A1 (en) 2015-01-16 2016-07-21 Öğün Yusuf Toktamiş Cefditoren pivoxil compositions with improved stability and production methods thereof
KR20180114177A (ko) 2016-02-26 2018-10-17 데비오팜 인터네셔날 에스 에이 당뇨병성 족부 감염의 치료제
CN109053768A (zh) * 2018-08-07 2018-12-21 中国医药集团总公司四川抗菌素工业研究所 一种无定型头孢妥仑酯的制备方法
CN110251467A (zh) * 2019-06-26 2019-09-20 北京济美堂医药研究有限公司 一种无定形态头孢妥仑匹酯组合物的制备方法
CN112190539B (zh) * 2020-11-10 2021-11-02 深圳立健药业有限公司 一种头孢妥仑匹酯组合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0678234B2 (ja) * 1988-04-19 1994-10-05 明治製菓株式会社 経口投与用抗菌組成物
JPH05306227A (ja) * 1992-04-27 1993-11-19 Lion Corp 徐放性口腔内疾患治療剤
JP2576927B2 (ja) * 1992-05-15 1997-01-29 ファイザー製薬株式会社 細粒核
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
JPH0717866A (ja) * 1993-06-16 1995-01-20 Meiji Seika Kaisha Ltd 医薬組成物
AR004014A1 (es) * 1995-10-13 1998-09-30 Meiji Seika Kaisha Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion
NZ334883A (en) * 1996-09-20 2000-09-29 Meiji Seika Kaisha A crystalline substance of cefditoren pivoxil which has desirable thermal storage stability and the production of the same
PL194097B1 (pl) * 1998-01-07 2007-04-30 Meiji Seika Kaisha Kompozycja zawierająca krystalograficznie trwałą amorficzną cefalosporynę i sposób jej wytwarzania

Also Published As

Publication number Publication date
TW587946B (en) 2004-05-21
UA70311C2 (uk) 2004-10-15
EA200000742A1 (ru) 2001-02-26
ES2393972T8 (es) 2013-02-25
WO1999034832A8 (fr) 1999-10-28
EP1051978A4 (en) 2007-05-02
BRPI9907084B8 (pt) 2021-05-25
TR200001903T2 (tr) 2000-11-21
CZ302082B6 (cs) 2010-09-29
SK10262000A3 (sk) 2001-01-18
ES2393972T3 (es) 2013-01-03
IL137004A (en) 2008-11-03
HU230295B1 (hu) 2015-12-28
EA002881B1 (ru) 2002-10-31
EP1051978B1 (en) 2012-08-22
WO1999034832A1 (fr) 1999-07-15
SK286631B6 (sk) 2009-02-05
AU1784599A (en) 1999-07-26
BRPI9907084B1 (pt) 2017-04-25
PL341589A1 (en) 2001-04-23
CN1290177A (zh) 2001-04-04
US6342493B1 (en) 2002-01-29
CN1151845C (zh) 2004-06-02
HUP0101272A2 (hu) 2001-12-28
AU736555B2 (en) 2001-08-02
US20020037322A1 (en) 2002-03-28
CA2316841C (en) 2007-11-20
EP1051978A1 (en) 2000-11-15
US6486149B2 (en) 2002-11-26
PT1051978E (pt) 2012-11-20
KR20010033961A (ko) 2001-04-25
ID25469A (id) 2000-10-05
CZ20002542A3 (cs) 2000-12-13
KR100435315B1 (ko) 2004-06-10
CA2316841A1 (en) 1999-07-15
JP3413406B2 (ja) 2003-06-03
HK1035148A1 (en) 2001-11-16
NZ505871A (en) 2002-10-25
IL137004A0 (en) 2001-06-14
HUP0101272A3 (en) 2002-07-29
PL194097B1 (pl) 2007-04-30

Similar Documents

Publication Publication Date Title
BR9907084A (pt) &#34;composição em pó, de cor amarela, administrável oralmente, e processo para a preparação da mesma&#34;
BR0211028A (pt) Solução aquosa, método para formação de associações de fármaco e polìmero, composições farmacêuticas, método para formação de uma composição farmacêutica e produto
CA2334773A1 (en) Benzothiepine-1,1-dioxide derivatives, method for producing them, medicaments containing these compounds and their use
BR0007781A (pt) Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf
BG103945A (en) Derivatives of 4&#34;-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
CA2316919A1 (en) Novel macrolides
BG100946A (en) New amino acid derivatives, method for their preparation and pharmaceutical compositions containing them
ATE233752T1 (de) Liponsaürederivate, deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
HUT70768A (en) N-containing cyclic compounds, pharmaceutical compositions containing them, and process for producing them
BR0016879A (pt) Métodos para transferência de interleucina-2 por via pulmonar
HUT67653A (en) Nor-bile-acid derivatives, process for producing them and pharmaceutical compositions containing them
YU70901A (sh) Derivati 1,4-benzotiazepin-1,1 dioksida zamenjeni radikalima šećera, postupak za njihovu proizvodnju, lekovi koji sadrže ova jedinjenja i njihova primena
BR0001468A (pt) ácidos dioxiciclopentil hidroxânicos
BG103947A (en) Derivatives of 9-oxymerythromycin
YU75403A (sh) Vodeni amfotericin b preparat
EP0992509A3 (en) Novel macrolide derivatives
CA2317465A1 (en) Synthetic polysaccharides, their method of production and pharmaceutical compositions containing same
AP9801377A0 (en) Tricyclic erythromycin derivatives.
EP0233946A4 (en) CHROMOGLYCIC ACID DERIVATIVES, PREPARATION METHOD AND MEDICINAL COMPOSITION.
EP0105210A3 (en) Isoquinoline derivatives, process for their preparation, pharmaceutical compositions containing them and their use
DE50204789D1 (de) Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
BR0005392A (pt) Composição de dhea e processo
HUT40640A (en) Process for producing 1,4-dihydro-3-carboxy-4-oxo-quinoline derivatives and pharmaceutical compositions containing them
AU636178B2 (en) 7 (alanylaminothiazol-iminoacetamide) substituted cephalosporin derivatives
IL148739A0 (en) 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 9/14, A61K 31/545, A61K 31/546, C07D 501/00, C07D 501/24

Ipc: A61K 47/38 (2009.01), C07D 501/24 (2009.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIDO O PEDIDO COM BASE NOS ARTIGOS 8O,13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09Y Publication of grant cancelled [chapter 9.1.2 patent gazette]

Free format text: REFERENCIA RPI 2147- CODIGO 9.1

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: MEIJI SEIKA KAISHA, LTD (JP)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 20120104493/RJ, DE 08/11/2012, E NECESSARIO APRESENTAR O DOCUMENTO DE ALTERACAO DE NOME NOTARIZADO E COM A DEVIDA LEGALIZACAO CONSULAR.

B25F Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement

Owner name: MEIJI SEIKA KAISHA, LTD (JP)

Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 20130077706/RJ DE 23/09/2013, E NECESSARIO APRESENTAR O DOCUMENTO DE ALTERACAO NOTARIZADO E COM A DEVIDA LEGALIZACAO CONSULAR.

B25E Requested change of name of applicant rejected

Owner name: MEIJI SEIKA KAISHA, LTD (JP)

Free format text: INDEFERIDO(S) O(S) PEDIDO(S) DE ALTERACAO(OES) DE NOME CONTIDO(S) NA PETICAO NO 20120104493, DE 08/11/2012, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2291, DE 02/12/2014.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B25D Requested change of name of applicant approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/01/1999 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 07/01/2019